GNKG 168

Drug Profile

GNKG 168

Alternative Names: CpG 685; CpG ODN; GNKG168

Latest Information Update: 28 Oct 2015

Price : $50

At a glance

  • Originator Changchun Huapu Biotechnology
  • Developer SBI Biotech
  • Class Antineoplastics; Nucleic acids; Oligonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 28 Oct 2015 Discontinued - Phase-I for Chronic lymphocytic leukaemia in USA (IV)
  • 10 Jan 2015 No development reported - Phase-I for Chronic lymphocytic leukaemia in USA (IV)
  • 30 Sep 2011 Phase-I development is ongoing in USA (NCT01035216)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top